- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Stada Launches Bevacizumab Biosimilar
Seeking to develop a biosimilar portfolio, Stada Arzneimittel has launched Oyavas in Germany and the Netherlands.
Stada Arzneimittel has received European Commission approval for the bevacizumab biosimilar Oyavas and has immediately launched the product in Germany and the Netherlands.
“Launches in other European countries will follow soon, depending in part on national pricing and reimbursement clearance,” the company said in a statement.
The launch is in partnership with mAbxience, which is an established biosimilar supplier in Latin America.
Stada, based in Bad Vilbel, Germany, said data submitted for the European marketing authorization demonstrated that the biosimilar is equivalent to the reference product (Avastin) in terms of quality, safety, and efficacy for the treatment of colon, rectal, breast, and non–small cell lung cancers, in addition to epithelial ovarian, fallopian tube, cervical, and primary peritoneal cancers.
“Through partnerships, STADA has built a comprehensive biosimilars portfolio and pipeline, not only in oncology, but also in therapeutic areas such as autoimmune disorders, osteoporosis, and ophthalmology, as the group continues to strengthen its presence in the specialty pharma sector, said Stada CEO Peter Goldschmidt.
Also of Note
mAbxience recently announced plans to strengthen its biosimilar production capacity in Leon, Spain.
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
January 19th 2025The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Improving Biosimilar Access Through Global Regulatory Convergence
January 15th 2025Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.
